Yongchang Qiu, PhD

Dr. Yongchang Qiu is the founder and CEO of Lysoway Therapeutics. Previously, he was Head of Translational Sciences at Shire (supporting 70+ development programs) and Director of Translational Research at Genzyme (responsible for preclinical pharmacology and biomarker development for multiple rare disease programs). He also was Vice President of Preclinical Development at Cydan (a rare disease venture/accelerator company), responsible for the entire pre-clinical development portfolio. Earlier in his career, he acted as Head of Proteomics at Wyeth. He has directly contributed to numerous regulatory filings, including over 10 INDs and 6 NDAs. Dr. Qiu earned his PhD in Pharmaceutical Chemistry and Biopharmaceutical Sciences at University of California at San Francisco, an MS in Organic Chemistry at New York University and a BS in Chemistry from University of Science and Technology of China. Dr. Qiu has authored 50+ peer-reviewed research articles and 15+ original patents covering a variety of therapeutic areas.